Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
12.21
-0.16 (-1.29%)
Feb 21, 2025, 4:00 PM EST - Market closed
Tourmaline Bio Employees
Tourmaline Bio had 44 employees as of December 31, 2023.
Employees
44
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,451,750
Market Cap
313.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
TRML News
- 6 weeks ago - Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker - GlobeNewsWire
- 2 months ago - Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day - GlobeNewsWire
- 3 months ago - Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 - GlobeNewsWire
- 3 months ago - Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - Tourmaline Bio to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 - GlobeNewsWire
- 4 months ago - Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting - Seeking Alpha
- 4 months ago - Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - GlobeNewsWire